Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles
In decades, radioiodine therapy has been a cornerstone in managing differentiated thyroid carcinoma (DTC) [1]. Recent paradigms on the use of radioiodine therapy have changed, and selective use of radioiodine therapy as postoperative adjuvant therapy is being considered [2]. Although radioiodine therapy is considered reasonably safe compared to other cancer treatment modalities, potential complications cannot be completely eliminated. In addition to early onset adverse effects, there are increasing reports of late onset adverse effects in long term survivors previously treated with radioiodine therapy, including second primary malignancies [3,4].
Source: Oral Oncology - Category: Cancer & Oncology Authors: So Young Park, Hye In Kim, Joon Young Choi, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Soo Hyun Ahn, Kyunga Kim, Jong Gill Jeong, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Oral Cancer | Radioiodine Therapy | Thyroid | Thyroid Cancer